AFT upgrades guidance following maiden US sale

AFT upgrades guidance following maiden US sale
Managing director Hartley Atkinson says he's confident AFT's investments will reward shareholders over the medium to long term. (Image: Supplied)
John Anthony
Dual-listed pharmaceutical company AFT Pharmaceuticals has lifted its profit guidance for the year to March following the first sale of its intravenous pain-relief medicine in the United States.AFT expects operating profit to range between $23 million and $25m, up on earlier guidance of $22m to $24m.US successIn a statement to the Australian securities exchange (ASX) and New Zealand stock exchange (NZX) on Friday morning, AFT said the update followed a review of January trading and news that Hikma Pharmaceuticals, the US licensee of its pain-re...

More Markets

NZ sharemarket flat amid Tourism Holdings trading halt
Markets Market close

NZ sharemarket flat amid Tourism Holdings trading halt

The S&P/NZX 50 Index closed at 11,874.04, up 6.46 points or 0.05%.

THL halts trading on 'materially lower' earnings expectations
Markets

THL halts trading on 'materially lower' earnings expectations

In February THL's net profit guidance for FY2024 was $75m.

BNZ's 1H profit and margins ease
Markets

BNZ's 1H profit and margins ease

Net profit was down 5.3% on the previous year's first half. 

NZ sharemarket falls due to global inflation fears
Markets Market close

NZ sharemarket falls due to global inflation fears

The S&P/NZX 50 Index closed at 11,867.58, down 89.92 points or 0.75%.

Graham Skellern 01 May 2024